Protocol Ledger

NCT04221438 · Phase II · TERMINATED

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Interventional Phase II clinical trial protocol NCT04221438 sponsored by ECOG-ACRIN Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-22 Enrollment: 3 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04221438
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04221438
Protocol FieldVerified Registry Value
NCT IdentifierNCT04221438
Consolidated Lead SponsorECOG-ACRIN Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment3 participants (ACTUAL)
Registered Start Date2021-09-22
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI